Jo Varshney, PhD, DVM, discusses how VeriSIM Life’s innovative approach leverages artificial intelligence and multispecies ...
A new working paper has found that one-third of all data points collected in 105 phase 2 and 3 trials were not needed for the studies’ key analyses, while also highlighting how an increase in clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback